← Evidence map

ReviewBiomedicines2026

"Carry-Over" Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular Approach.

Guillermo Valencia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

"Carry-Over" Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular Approach. | Socratic